How are you feeling today? Keep up to date on news and stories related to health care here!
New York City subway and bus riders who are caught not wearing a mask will soon face $50 fines, Gov. Andrew Cuomo and transit officials announced Thursday. — FOX News: Greg Norman
A participant in the company’s late-stage coronavirus vaccine trial reportedly developed severe neurological symptoms. Now experts must assess whether the vaccine was responsible. — NYT: Katherine J. Wu
Susan M. O’Brien, M.D., one of the nation’s foremost leukemia experts, discusses the future of frontline therapies and upcoming clinical trials associated with chronic lymphocytic leukemia. CRANBURY, N.J.–(BUSINESS WIRE)–#BloodCancerAwarenessMonth–In support of Blood Cancer Awareness Month and World Lymphoma Awareness Day, the CURE®
New studies show caregivers with young children are stressed, with no signs of relief on the horizon. — NYT: Jessica Grose
Leading behavioral care provider also introduces nationwide availability of new mental health coaching services and expands therapy offering to 10 states MINNETONKA, Minn.–(BUSINESS WIRE)–Sanvello Health, Inc., a leading digital mental health care provider and a UnitedHealth Group (NYSE: UNH) company, today announced
CAMDEN, N.J.–(BUSINESS WIRE)–Rondo-Pak, LLC, a Joint Venture with Körber Pharma group (formerly Körber Medipak Systems), has named Bob Reilley as its President and Chief Operating Officer. Mr. Reilley had been in the COO role for 4 years. As President and COO he
OLDWICK, N.J.–(BUSINESS WIRE)–Canada’s property/casualty insurance industry thus far has fared better than their life counterparts amid the volatile economic and market dynamics created by the COVID-19 pandemic, according to a AM Best report. In its Best’s Market Segment Report, titled, “COVID-19 Taking
Lawmakers are also facing a potential government shutdown that could prolong the economic pain. Nine drugmakers are pledging to thoroughly vet any coronavirus vaccine.
Companies will partner to develop novel antibody-drug conjugates using Catalent’s SMARTag bioconjugation platform and monoclonal antibodies from Exelixis’ growing preclinical pipeline Agreement includes exclusive options on multiple targets over three-year term, with potential to extend time and scope of the collaboration Deal